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Abstract 
A Novel Human Adipocyte-derived Basement Membrane for 
Tissue Engineering Applications 
by 
Aaron Damm 
 
Tissue engineering strategies have traditionally focused on the use of synthetic 
polymers as support scaffolds for cell growth. Recently, strategies have shifted towards a 
natural biologically derived scaffold, with the main focus on decellularized organs. Here, 
we report the development and engineering of a scaffold naturally secreted by human 
preadipocytes during differentiation. During this differentiation process, the 
preadipocytes remodel the extracellular matrix by releasing new extracellular proteins. 
Finally, we investigated the viability of the new basement membrane as a scaffold for 
tissue engineering using human pancreatic islets, and as a scaffold for soft tissue repair. 
After identifying the original scaffold material, we sought to improve the yield of 
material, treating the cell as a bioreactor, through various nutritional and cytokine stimuli. 
The results suggest that adipocytes can be used as bioreactors to produce a designer-
specified engineered human extracellular matrix scaffold for specific tissue engineering 
applications.   
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Chapter 1 
1 Introduction 
Previously, tissue and organ replacement has been limited to either transplantation 
with donor tissue or more recently, replacement with synthetic biomedical devices. 
However, both strategies suffer from significant disadvantages. Transplantation is limited 
by the number of healthy organ donors as well as viability of donated organs. While 
biomedical devices do not suffer from limited number, they lack the same self renewal 
properties of native tissue. To combat these shortages, researchers have taken up the field 
of tissue engineering. Tissue engineering was defined by Langer et al. as an 
interdisciplinary field that applies the principles of engineering and life sciences toward 
the development of biological substitutes that restore, maintain, or improve tissue 
function [1]. Current tissue engineering strategies focus on replicating the native 
extracellular matrix (ECM) through either synthetic or natural, biologically-derived, 
scaffolds composed of engineered polymers or proteins. Synthetic scaffolds have evolved 
from basic building blocks into complex polymer scaffolds chemically constructed to 
promote cell adhesion [2]. Nearly all synthetic scaffolds are derived from a small group 
of materials originally used as degradable suture material. The most commonly used 
materials are poly(glycolic acid) (PGA) and poly(lactic acid) (PLA) from the poly(α-
hydroxyesters) [3]. These scaffolds offer the promise of cost-effectiveness and 
reproducibility with defined mechanical characteristics as well as degradation in vivo. 
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While synthetic scaffolds have shown promising results and advanced designs, these 
materials also introduce foreign agents into the body and have difficulty in mimicking the 
complexity of the native extracellular matrix.  
 Biologically-derived extracellular matrix increases the complexity of the 
engineered scaffold, but suffers from undefined composition, difficulty in reproduction, 
and lack of donor tissue. Numerous methods have been developed for isolating natural 
ECM from a variety of sources, primarily using a decellularization process [4-7].  One of 
the most promising methods is the use of sacrificial open celled foams for in vitro 
expansion of ECM secreting cells [8]. In this method, the cells are removed from the 
foam leaving behind the synthesized ECM, then the foam is chemically degraded leaving 
behind only the secreted ECM. A similar method uses progenitor cells to deposit a native 
extracellular matrix on a titanium scaffold to enhance biological activity of the scaffold 
[9]. The progenitor cells are removed from the scaffold after depositing an ECM layer on 
the scaffold, and the scaffold is reseeded with marrow stromal cells to be differentiated in 
to osteoblastic cells. Both methods have shown promising results for producing ECM and 
enhancing the effectiveness of current scaffolds. However, these methods are still 
dependent on donor tissue (decelluarized organs) and enzymatic or chemical procedures 
for isolation of the ECM. Biological ECM derived from animals is also limited by the 
structure and composition of the harvested tissue, because it does not perfectly match the 
characteristics of human ECM. Nevertheless, the use of cells to deposit ECM in vitro for 
use as a scaffold has lead to the development of cell synthesized ECM processes. 
Another commercially viable source of human ECM proteins is through genetic 
engineering. Researchers have successfully produced human collagen from bacteria [10], 
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yeast [11], Chinese ovarian hamster cells [12], and HeLa cells [12, 13]. Since in vivo 
collagen synthesis is an intricate process and essential for cell survival, recombinant 
collagen is unable to identically match the native collagen conformation [14, 15]. 
However, methods using recombinant collagen have been used to create scaffolds for 
skin and bone engineering applications. The combination of genetic engineering and cell 
deposited ECM processes has culminated in the development of human cell secreted 
ECM capable of modulation to produce designer specific scaffolds. 
Recently, bioengineers have produced a new type of biological ECM. This is cell-
secreted extracellular matrix (CS-ECM), an ideal biomaterial for tissue engineering [9, 
16, 17]. CS-ECM is produced by cells in culture and can either be used as a reconstituted 
ECM or as a decellularized construct. Native tissue consists of a variety of cell types and 
the extracellular matrix secreted by them. Native extracellular matrix is known to be 
involved in cell signaling, mobility, and proliferation. This matrix provides the ideal 
environment for cell growth and adhesion. ECM deposited by cells in vitro can be 
collected to produce human derived biologically active materials. Okano pioneered a 
method of cell sheet engineering using temperature sensitive poly(N-isopropylacrilamide) 
(PI-PAAm) [18]. When the polymer surface is cooled below 32oC, the surface is becomes 
hydrophilic, resulting in spontaneous cell detachment. The detached sheets contain viable 
cells, intact cell to cell junction proteins, growth factor receptors, as well as deposited 
ECM [19]. Okano also demonstrated the usefulness of this approach for islet 
transplantation [20]. The islet cell sheets were then transplanted and maintained their 
functionality for 7 days in vivo. However, the thickness of the sheetness makes them a 
less viable method for larger tissues even though they can be stacked together. 
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CS-ECM may hold the key to overcoming current obstacles in scaffold 
development. CS-ECM can be obtained from cultured cells, thus overcoming the need for 
donor tissue. Also, several secretome profiling studies suggest that the composition of the 
secreted extracellular matrix is defined depending on the type of cell used. Cell-secreted 
ECM has shown promising results for numerous applications, from articular cartilage 
repair to bone replacement. Many of the advantages that cell-secreted ECM offers have 
yet to be fully developed or found. At the forefront of these advantages is the ability to 
metabolically engineer human cells to produce large quantities of a targeted tissue-
specific ECM. For example, long-term culture in ascorbic acid has been shown to 
promote collagen synthesis in skin fibroblasts [21]. Another study by Mikos et al. uses 
shear stress to induce ECM generation by rat marrow stromal cells [22]. These studies 
suggest that, depending on the culture conditions and substrates available, mammalian 
cells can be manipulated to produce desired protein products. Another advantage of cell-
secreted ECM is that pathogens can be identified and removed in vitro, preventing host 
inflammatory response. Finally, CS-ECM inherently possesses the complexity of the 
native extracellular matrix required for cell signaling, cell repopulation, and ECM 
remodeling. These advantages have lead researchers to study the ECM generated by 
numerous cell types and sources.  
Cell-secreted extracellular matrix is a promising new material for tissue 
engineering applications, offering a naturally-derived material capable of mimicking the 
complexity of native ECM, while avoiding eliciting foreign body inflammatory responses 
from the host. Although most recent studies demonstrate the use of cell-secreted ECM 
from various cell sources as producing favorable results for enhancing cell proliferation 
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and function on decellularized polymer scaffolds, there remains the ability to use the 
ECM as reconstituted scaffold similar to matrigel, capable of taking different geometries 
based on application constraints. Future work with cell-secreted ECM also elicits ideas of 
metabolically engineering mammalian cells for production of large quantities of ECM 
containing high concentrations of vital growth factors. While the use of multiple cell 
types that can be co-cultured and metabolically manipulated to produce a biomaterial that 
resembles the native structure of the desired tissue has yet to be established, cell-secreted 
ECM holds the promise of producing an ideal biomaterial for tissue engineering.  
1.1 Outline 
In the next chapter, we investigate the ECM production abilities of Simpson-
Golabi-Behmel Syndrome (SGBS) preadipocytes. Different time periods were studied for  
their ability to produce the highest concentration of ECM proteins during differentiation. 
The final, concentrated form of the secreted protein is called humalipogel for the 
purposes of this study.  In Chapter 3, we use our newly created humalipogel as an ECM 
scaffold for pancreatic islet cultures. We investigated the material’s effect on Islet 
morphology, integrity and also their function through measurements of their insulin 
content and stimulation index (SI). Chapter 4 investigates the use of humalipogel as a 
scaffold for soft tissue repair. We investigate the adipogenic potential through inducing 
adipocyte differentiation and observing the results with Oil Red O staining.  Chapter 5 
builds on the findings of Chapter 2, as we develop a method for enhancing the production 
of protein from SGBS preadipocytes during differentiation. The focus is primarily on 
manipulating the protein content through various nutritional, cytokine and mechanical 
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stimuli. In the last chapter, we will discuss the future direction of this CS-ECM scaffold 
and summarize the various advantages that have been identified thus far.
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  Chapter 2 
2 Engineering a Human Adipocyte-derived Extracellular 
Matrix Scaffold 
2.1 Introduction 
Recently, researchers have begun investigating the use of natural extracellular matrix 
deposits on synthetic scaffolds. A study done by Chen et al investigated the effects of 
human mesenchymal stem cells (hMSCs), fibroblast and chondrocyte cultured cell-
derived extracellular matrices on hMSCs and fibroblasts. To produce the cell-derived 
matrices, either fibroblasts, hMSCs or chondrocytes were grown on polymer scaffolds for 
an extended period of time, and then each construct was decellularized. The remaining 
construct contained the secreted ECM and was re-seeded with hMSCs or fibroblasts. 
While this study did not compare hMSC-derived scaffolds with fibroblast-derived 
scaffolds directly, both constructs showed higher proliferation, bioactivity and filled in 
the voids in the construct with their own ECM after re-seeding with the same cell type. 
The researchers were able to show that the natural cell-derived ECM is a viable option 
for improving polymer scaffolds. They also kindled the idea of using different cell types 
for specific applications. 
Rat tail collagen and Matrigel are popular reconstituted ECMs currently used for 
in vivo 3D tissue cultures and are models for reconstituted cell-secreted ECM. A study 
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done by Leach et al cultured human mesenchymal stem cells on tissue plastic to generate 
a matrix for accelerating the osteogenic differentiation of hMSCs [23]. The cell-secreted 
matrix was collected from the original well after decellularization, purified and re-seeded 
on another cell culture plate for use with hMSCs. While the main goal of the study was to 
accelerate differentiation, the ability to transfer the matrix to another well shows the 
viability of cell-secreted matrices as reconstituted ECM. These soft gels have the ability 
to adapt to nearly any geometry while maintaining structural integrity. Researchers at 
Harvard University have demonstrated the ability to create a cell-secreted ECM gel 
similar to collagen from 3T3-L1 mouse preadipocytes [17]. This mammalian matrix 
demonstrated the ability to improve rat hepatocyte function in 3D cultures when 
compared to the current standard collagen sandwich culture. When a drop of this 
concentrated ECM was placed on a petri dish, the ECM held the droplet shape and did 
not disperse, demonstrating its potential as a soft moldable scaffold.   
 With the goal of generating a natural human-derived ECM scaffold safe for 
human transplantation, we focused our efforts on preadipocytes because of the abundance 
of subcutaneous fat in the body and previous success with mouse preadipocytes.  We 
chose to work with SGBS preadipocytes due to their recognition as a model for human 
subcutaneous preadipocytes and their primary cell lineage [24]. 
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2.2 Materials and Methods 
2.2.1 Cell Culture 
Simpson-Golabi-Behmel Syndrome preadipocytes were obtained from Dr. Martin 
Wabitsch. The SGBS cell line is grown in media, OF, containing DMEM nutrient 
mixture supplemented with 2% penicillin/streptomycin mixture, 10% fetal bovine serum, 
and 2.2 g sodium bicarbonate until confluency. The media is then changed to 
differentiation media, Day 0. The differentiation media consists of DMEM/F12 nutrient 
mix supplemented with 0.008 g biotin, 0.004 g pantothenate, 2% penicillin/streptomycin, 
0.01 mg/mL human transferrin, 0.02 units/mL insulin, 100 nM cortisol, 0.2 nM T3, 25 
nM dexamethasone, 50 μM 1-methyl-3-isobutylmethylxanthine (IBMX) and 2μM 
rosiglitazone. The cells are cultured with the differentiation media for 4 days. On Day 4 
the media is collected, labeled and stored at -20 OC. The differentiation media is replaced 
with maintenance media consisting of DMEM/F12 mix supplemented with 0.008 g 
Biotin, 0.004 g pantothenate, 2% penicillin/streptomycin, 0.01 mg/mL human transferrin, 
0.02 units/mL insulin, 100 nM cortisol, 0.2 nM T3 and 2 μM rosiglitazone. The media is 
then collected on days 8 and 12. The collected media is filtered using a 20 mL centrifuge 
filter for material greater than 100,000 MWCO or 100 kDa. A 100 kDa filter size was 
used to retain only the large ECM proteins secreted in to the exposed media. The 
retentate from this filtration is the concentrated material and is the gel used for different 
applications. The gel is then used as either a scaffold for cell culture or as a media 
supplement to promote cell adhesion. Images were acquired after 0, 4, 8 and 12 days of 
culture to verify differentiation efficiency with the accumulation of lipid droplets in the 
differentiated adipocytes. 
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2.2.2 Protein Content Determination 
Protein content was determined using BCA assay (Pierce) with Bovine Serum 
Albumin (BSA) as standard. Briefly, 10 μL samples were added to 200 μL of reagent 
based on bicinchoninic acid, inducing a color change. The absorbance was then measured 
at 562 nm. The protein concentration in the sample was determined based on standard 
curves to yield total protein content of the samples. 
2.2.3 Western Blot 
Total material (10 μg/lane) was resolved by SDS-PAGE and transferred to PVDF 
membranes. A primary antibody against laminin (Santa Cruz) was used. Rabbit 
secondary antibodies were used at dilutions of 1:500.   
2.2.4 Experimental Design 
 
Figure 1: Adipose-derived ECM generation 
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2.3 Results 
Adipocyte differentiation was confirmed through bright field imaging and Oil Red 
O staining of untreated preadipocytes (control) and treated preadipocytes (normal). 
Bright field imaging confirmed the morphology- a rounded shape with large lipid 
droplets throughout the cytoplasm- of the adipocytes, and revealed lipid droplet 
formation over the course of differentiation (Figure 2). The treated preadipocytes stained 
positive for lipid droplets as seen in Figure 3 while the untreated preadipocytes did not 
show staining for lipid droplets, further confirming adipocyte differentiation in the test 
group.  
To determine the optimum collection day for secreted proteins, we measured 
protein content in the concentrated and unconcentrated media for days 4, 8 and 12. 
Significant material was obtained after collection and filtration. On average for days 4 
and 12, 100 μL of material was obtained per 20 mL of media concentrated, while day 8 
produced 200 μL of material per 20 mL of collected media. Protein measurements were 
made before and after filtration. Before filtration, all days had elevated levels of protein 
content when compared to the control media as seen in Figure 4. Days 8 and 12 increased 
protein content to 913.76 ± 70.5 μg/mL and 958.60 ± 35.93 μg/mL respectively. Day 4 
had the largest increase in protein content to 1053.38 ± 65.33 μg/mL. After filtration, all 
days showed significant increase in protein content over the fresh unexposed media in 
Figure 5. Days 4 and 12 increased protein content on average 8-fold over the normal 
media to 6,000 μg/mL. Day 8 showed the greatest increase in protein content to 22,500 
μg/mL, an over 30-fold increase. To verify the presence of extracellular matrix proteins 
in the collected media, we performed western blotting for laminin. Western blotting 
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revealed the presence of laminin, an extracellular matrix protein, in the filtered material 
as shown in Figure 6. 
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Figure 6: Western blot of Laminin in concentrated adipocyte secreted ECM 
2.4 Discussion 
The extracellular matrix is a complex and intricate material that provides 
structural and functional support comprised of glycoproteins, fibronectin, collagens, 
laminins, and growth factors. The exact composition of the extracellular matrix varies 
based on cell phenotype and function. Due to the complexity of natural ECM, a natural in 
vitro cell culture system capable of generating sufficient amounts of ECM with growth 
factors has to be established. As previously mentioned, numerous cell types produce 
natural ECM, but they do not produce sufficient material. We have developed a novel 
human preadipocyte differentiation system capable of generating substantial amounts of 
ECM.  
When confluent SGBS preadipocytes were cultured in the serum free DMEM/F12 
media without adipogenic factors, the cells did not undergo differentiation, indicating 
there is no self-differentiation potential. When adipogenic factors (insulin, cortisol, 
triiodothyronine, rosiglitazone, dexamethasone, and IBMX) were introduced to confluent 
SGBS preadipocytes in serum free DMEM/F12, the majority of SGBS cells differentiated 
into mature adipocytes as seen in Figure 2. During the differentiation period, the cells 
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accumulated lipids and displayed a round shape with a cytoplasm full of lipid droplets 
which are visual markers for fully differentiated adipose cells. Oil Red O staining 
confirmed the presence of lipid droplets in the cytoplasm of the treated cells, which is 
consistent with previously reported data by Wabitsch et al [24].  
When the cell-exposed media was collected, there was a noticeable difference in 
consistency between the fresh media and exposed media. Rosenow et al previously 
studied the secretome of SGBS cells pre- and post-differentiation and identified 
numerous ECM proteins and growth factors in the secretome but did not quantify the 
protein secretion levels [25]. Our results are consistent with these findings. Protein 
secretion levels were significantly elevated during differentiation, and western blotting 
confirmed the presence of laminin, an extracellular protein, in the concentrated media. 
However, the concentrated and unconcentrated forms of material revealed different 
trends in protein secretion. The unconcentrated protein content was highest on Day 2 and 
continued to decrease over the course of differentiation. The concentrated protein content 
had a bell-shaped trend with the highest protein content on Day 8, followed by Day 4 and 
the lowest on Day 12. Since a 100 kDA filter was used for concentration, this trend 
suggests that large proteins are secreted primarily on Day 8 while smaller proteins are 
secreted earlier in the differentiation process on Days 2 and 4. Since the smaller proteins 
are likely growth factors and signaling molecules, for certain applications a smaller filter 
size could be used on the filtrate to collect these proteins and combine them with the 
larger ECM proteins for an ideal scaffold. 
The results of this experiment clearly show that during differentiation, SGBS cells 
secrete a protein mixture consisting of ECM proteins as well as growth factors identified 
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in previous studies of adipocyte differentiation [25]. The secreted protein mixture can be 
concentrated for potential use as a natural human-derived ECM scaffold for tissue 
engineering applications. We have labeled this concentrated protein mixture humalipogel. 
2.5 Summary 
The findings of this study indicate that the preadipocytes completely 
differentiated to mature adipocytes as seen by the Oil Red O staining and bright field 
imaging. Further, that during differentiation, the adipocytes secrete extracellular matrix 
proteins in varying amounts depending on the day of collection. Also, the secreted 
extracellular matrix proteins can be collected and filtered to yield a highly concentrated 
gel with greater than 20 times the protein found in normal media. Finally, the secreted 
matrix can be concentrated with potential use as a novel human-derived ECM scaffold, 
deemed humalipogel. Further work should focus on using different stimuli to increase 
and manipulate the composition of the secreted protein.
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Chapter 3 
3 Viability of Humalipogel as Tissue Engineering Scaffold 
3.1 Introduction 
Islet tissue engineering and regenerative medicine is one of the most promising 
and challenging fields for treating type 1 diabetes. The World Health Organization 
estimates 346 million people currently suffer from diabetes, and that 366 million people 
worldwide, nearly 4.4% of the total population of Earth, will suffer from diabetes by 
2030 [26]. Islet transplantation for type 1 diabetes patients offers the potential to stabilize 
glucose metabolism and prevent further diabetic complications. However, islets from 
more than one donor are generally required to achieve euglycemia, and transplant 
patients are still affected by reduced glucose-stimulated insulin secretion [27]. 
Furthermore, the majority of these treatments provide insulin independence for only five 
years [28]. While the causes of graft failure are not completely known, the disruption of 
the basement membrane and the vasculature structure are likely culprits [29, 30]. During 
isolation, the islets are enzymatically cleaved from the basement membrane, destabilizing 
the islets and disrupting the vascular connections. The basement membrane provides 
structural support, mediates adhesion, and activates chemical signaling pathways within 
the cells. When the islets are removed from the BM, they undergo apoptosis. Repairing 
the BM connections through the use of ECM components in islet cultures has been shown 
to increase islet survival and functionality [31]. More detailed studies have shown the 
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exact effect of different ECM proteins on the functionality of islets [32]. These studies 
found a direct correlation between Collagen I, Collagen IV, and islet adhesion and 
glucose metabolism as well as fibronectin and islet morphology and insulin release. The 
results of this study suggest that there exists an optimal concentration of each ECM 
component for preserving islets in vitro. Researchers have also shown the usefulness of 
polymer scaffolds coupled with various ECM components [33]. The scaffold was coupled 
with a combination of ECM components to preserve islet functionality in long term 
cultures. 
 Another important aspect of the native in vivo islet environment is the various 
growth factors constantly interacting with the islets, the most important of which is 
vascular endothelial growth factor (VEGF). Studies have shown that the inclusion of 
VEGF in islet media increased the functionality and survivability of islets over time [34]. 
All of these studies suggest that maintaining islet function in culture for transplantation 
will require the incorporation of ECM components, growth factors and nutrients.  
The new BM derived from murine adipocytes consists of ECM components that 
have been shown to have a positive effect on islets; these include fibronectin, collagen 
IV, hyaluronan, and laminin as well as various growth factors that promote islet function 
and viability such as vascular endothelial growth factor (VEGF) and adiponectin [17, 34]. 
Furthermore, work on human preadipocytes has shown that during differentiation to 
mature adipocytes, the preadipocytes secrete various ECM and growth factors as well 
[25].  The primary aim of this work was to investigate the effectiveness of our naturally-
derived human basement membrane extract (BME) for long term in vitro culture of 
human pancreatic islets. The effect of the produced BME on islet function was 
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determined by the glucose-stimulated insulin response test and calculation of the 
stimulation index. Insulin content was also measured to further demonstrate the islet 
function.  
3.2 Materials and Methods 
3.2.1 Islet Culture 
Aliquots from healthy human islet isolations were cultured in a serum-free media 
(SFM) containing 1% ITS, 1% L-glutamine, 1% antibiotic antimyotic solution, and 16.8 
μM/L zinc sulfate. Culture media was changed weekly during the culture period.  
3.2.2 Islet Seeding 
Type 1 collagen was prepared by extracting acid-soluble collagen from rat tail 
tendons. The control group was islets in suspension culture. For the single gel collagen 
and humalipogel overlay condition, 400 μL of a cold mixture, 9 parts 1.25 mg/mL rat tail 
collagen type 1 and 1 part 10X concentrated DMEM, was distributed in each well. For 
the double gel sandwich culture, 250 μL of a cold mixture, 9 parts 1.25 mg/mL rat tail 
collagen type 1 and 1 part 10X concentrated DMEM, was distributed in each well. For 
the embedded condition, 400 μL of a cold mixture, 9 parts 1.25 mg/mL rat tail collagen 
type 1 and 1 part 10X concentrated DMEM, was mixed directly with 100 islet 
equivalents and distributed in each well. To induce gelation, the coated plates were 
incubated for 60 minutes at 37oC.  After gelation, the single gel wells were seeded with 
100 islet equivalents (IEQ) each and 400 μL of CMRL media. The humalipogel overlay 
condition was seeded with 100 islet equivalents. After seeding, 50 μL of humalipogel 
was mixed with 400 μL of CMRL media by continuous pipeting and added to the 
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humalipogel wells. For the embedded condition, 400 μL of CMRL media was added to 
each well. For the double gel sandwich culture, 400 μL of CMRL media was added to 
each well. After 48 hrs, the media was removed and 250 μL of collagen mixture was 
added to the double gel wells. To induce gelation, the coated plates were incubated for 60 
minutes at 37oC. After gelation, 400 μL of media was added to the well. The media was 
collected and changed on Days 7 and 14.   
3.2.3 Glucose Stimulated Insulin Release Test 
The in vitro function of human islets was determined by measuring secreted 
human insulin using an ELISA kit (ALPCO Diagnostics, Windham, NH). The islets were 
incubated at 37 °C for 1 hr with MEM media containing low (0.6 mg/ml, basal) and high 
(3 mg/ml, stimulated) glucose concentrations. After incubation, supernatants were 
collected and analyzed for insulin release. Insulin secretion was expressed as μU/mL and 
the ratio of insulin level at 3 mg/mL glucose to the insulin level at 0.6 mg/mL glucose 
was used to calculate the stimulation index (SI). 
3.2.4 Islet Morphology 
Islet morphology was studied by light microscope photography. Pictures were 
taken using a camera at 20X magnification on days 1, 7 and 14. 
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3.2.5 Experimental Design 
 
Figure 7: Humalipogel viability experimental design 
3.3 Results 
To determine the effect of humalipogel on islet function maintenance in culture, 
we measured the stimulation index and insulin content as well as observing the 
morphology. The stimulation index (SI) is a measure of islet function calculated by 
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dividing the insulin released at high glucose concentrations by the insulin released at low 
glucose concentrations. An SI index greater than one signifies that the islets have retained 
their function and still respond to changes in glucose concentration, while an SI less than 
one is indicative of nonresponsive islets that have lost their function. The stimulation 
index for islets cultured in humalipogel overlay was measured on Day 7. The first trial 
was only 2 wells per condition as a proof of concept study. The Day 7 measurement was 
24 days post isolation.  The control group was islets in suspension culture with CMRL 
media. The SI was measured for islets cultured on a single collagen layer, double 
collagen layer, embedded in collagen, and single gel collagen with humalipogel overlay 
as shown in Figure 8. The SI for humalipogel was 1.35, double gel 1.26, embedded 1.14, 
control 1.13, and the single gel was 0.99. Figure 9 shows the insulin content per islet 
equivalent (IEQ) measured in microunits per milliliter (μU/mL). Insulin content for the 
control group and humalipogel overlay conditions were significantly higher than the 
other conditions at 58.6 μU/mL and 50.2 μU/mL respectively. The single collagen gel 
was 18.9 μU/mL, with the embedded islet gel insulin content at 16.8 μU/mL and the 
double gel insulin content at 14.1 μU/mL. 
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Figure 8: Stimulation Index, Trial 1 of Islets Seeded in Single, Double and 
Embedded Collagen and Humalipogel overlay 
 
Figure 9: Insulin Content, Trial Trial 1 of Islets Seeded in Single, Double and 
Embedded Collagen and Humalipogel overlay 
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The stimulation index (SI) for islets cultured in humalipogel was measured on 
Day 7. The second trial used 3 wells per condition for stimulation index at 100 IEQ as 
well as 3 wells for insulin content at 50 IEQ. The Day 7 measurement was 12 days post 
isolation.  The control group was islets in suspension culture. The SI was measured for 
islets cultured on a single collagen layer, double collagen layer, embedded in collagen, 
and single gel collagen with humalipogel overlay as shown in Figure 10. The SI for 
humalipogel was 2.39, single gel was 1.94, double gel 1.64, and embedded 1.63. Fresh 
isolated islets had a stimulation index of 7.95. Figure 11 shows the insulin content per 
islet equivalent (IEQ) measured in microunits per milliliter (μU/mL). Insulin content for 
the humalipogel overlay was second highest in the second trial, at 40.64 ± 5.9 μU/mL, 
while the highest insulin content was the double gel at 45.0 ± 3.6 μU/mL. The embedded 
condition and single collagen layer had an insulin content of 30.24 ± 5.5 μU/mL and 20.9 
± 3.5 μU/mL, respectively. 
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Figure 10: Stimulation Index, Trial 2 of Islets Seeded in Single, Double and Embedded 
Collagen as well as Humalipogel (*P≤0.05, ** P≤0.01, *** P≤0.001) 
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Figure 11: Insulin Content, Trial 2 of Islets Seeded in Single, Double and Embedded 
Collagen as well as Humalipogel (*P≤0.05, ** P≤0.01, *** P≤0.001) 
The stimulation index (SI) for islets cultured in humalipogel was measured on 
Day 7. The third trial was 3 wells per condition for stimulation index at 100 IEQ as well 
as 3 wells for insulin content at 50 IEQ. The Day 7 measurement was 13 days post 
isolation.  The control group was islets in suspension culture. The SI was measured for 
islets cultured on a single collagen layer, double collagen layer, embedded in collagen, 
and single gel collagen with humalipogel overlay as shown in Figure 12. A new condition 
was introduced for the third trial; islets were embedded in a combination of humalipogel 
and collagen at a ratio of 2:3. The SI for control group was 3.20 ± 0.19, single gel was 
1.53 ± 0.25, double gel 1.64 ± 0.33, and embedded 2.54 ± 0.36. The humalipogel 
performed the worst in the trial with an SI of 1.02 ± 0.16 for the humalipogel overlay 
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condition and 0.97 ± 0.06 for the humalipogel-collagen mixture. Figure 13 shows the 
insulin content per islet equivalent (IEQ) measured in microunits per milliliter (μU/mL). 
Insulin content for the control group was 87.6 ± 4.5 μU/mL. The single gel, double gel 
and embedded conditions all had similar insulin content at 63.7 ± 9.5 μU/mL, 64.3 ± 3.7 
μU/mL, and 61.9 ± 8.3 μU/mL. The humalipogel overlay and humalipogel-collagen 
mixture were significantly lower at 43.6 ± 6.3 μU/mL and 41.1 ± 5.5 μU/mL, 
respectively. 
 
 
Figure 12: Stimulation Index, Trial 3 of Islets Seeded in Single, Double and Embedded 
Collagen as well as Humalipogel overlay and Humalipogel/Collagen Embedded 
(*P≤0.05, ** P≤0.01, *** P≤0.001) 
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Figure 13: Insulin Content Trial 3 of Islets Seeded in Single, Double and Embedded 
Collagen as well as Humalipogel overlay and Humalipogel/Collagen Embedded 
(*P≤0.05, ** P≤0.01, *** P≤0.001) 
Since functionality of islets is closely tied to islet morphology, we studied the 
morphology of islets using light microscope photography at 20X magnification, Figure 
14. The control group is the suspension culture and shows islets with their solid edges 
intact on day 7 and 14. The single collagen gel islets showed only partial morphology 
breakdown on day 7 and significant morphology changes on day 14 as seen by the lines 
extruding from original islet borders. The double collagen gel and embedded condition 
both maintained islet morphology with slight changes seen on day 14.  The humalipogel 
overlay shows significant changes in morphology on day 7 and day 14. On day 7 there is 
a noticeable spidering effect coming from the islets, and on day 14 the effect has nearly 
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interconnected islets. Some islets in humalipogel overlay showed an emptying of the 
islets with significant cell numbers extending from the empty shell, as seen in Figure 14.  
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Figure 14: Islet morphology on days 7 and 14 in culture 
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3.4 Discussion 
To improve the success rate of islet transplantation, we investigated the effect of 
our human humalipogel on human pancreatic islets.  While the main cause of failures in 
islet grafts has not been identified, a leading candidate is the disruption of the islet ECM 
environment resulting in the loss of islet function and islet cell death [35].  The 
functionality of islets in culture is also linked to their morphology [36]. Since the human 
humalipogel is composed of human ECM isolated from adipocytes, the humalipogel 
could be able to mimic the islet ECM microenvironment.  
Examination of the islet morphology revealed significant changes in boundaries 
of the islets. In the single collagen gel, the islets began to spread out from the original 
islet boundary with a web-like appearance, while the embedded and double gel displayed 
little or no change in their boundaries, consistent with previous studies [31]. However, 
the humalipogel condition also experienced significant spreading from the original 
boundaries. Since there is a second layer of ECM over the islets, they were not expected 
to spread out and were expected to behave similarly to the double gel conditions. The 
spreading effect may be due to adding humalipogel in small quantities over the course of 
several days instead of a large amount of humalipogel at once to form a complete second 
layer of ECM construct over the islets. However, when the humalipogel islets were 
stained (data not shown) for insulin, the cells branching out from the islet boundaries 
stained positive for insulin. This suggests that the cells breaking out of the islet are β -
cells that have either migrated from the islet or are newly formed β -cells. While β -cell 
proliferation was not thought to occur previously, there is recent evidence supporting β -
cell proliferation in rare instances [37].  
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For the first trial, the glucose challenge test clearly indicated that islets cultured 
with humalipogel had a higher functionality than islets cultured only in the presence of 
collagen. This result prompted a more comprehensive study of the effect of humalipogel 
on islet function in vivo. The second trial demonstrated the same increased SI in 
humalipogel as compared to the other conditions. The increased stimulation index 
suggests that the combination of ECM proteins in the humalipogel provides a favorable 
environment over only collagen IV. The suggestion that a mixture of ECM proteins 
would more closely mimic the native islet environment is supported by recent evidence 
that each ECM protein is responsible for different interactions with islets, with a mixture 
of ECM proteins resulting in the optimal environment for islet function [32].  The higher 
functionality of the islets in humalipogel was further confirmed by insulin content 
measurements, where the humalipogel had the highest insulin content except for the 
double gel. This suggests that not only does the humalipogel increase the islet stimulation 
index, but it also increases the islet glucose sensitivity.  
However, the increased stimulation index was lower than expected values when 
compared to previously reported data for ECM effect on islet function [33]. Furthermore, 
based on the morphology of the embedded collagen islets and previous studies supporting 
the use of three dimensional culture conditions, a new condition embedding islets in a 
mixture of collagen and humalipogel at a 3:2 ratio was proposed. For the third trial, the 
digestion procedure was modified for glucose challenge testing from mechanical 
digestion to collagenase digestion. With this change, the stimulation index of the 
humalipogel cultured islets decreased significantly. It is well known that islets exposed to 
collagenase for extend periods of time begin to break down.  A possible explanation is 
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that the collagenase damaged the islets in the humalipogel because of the decreased 
collagen content in the gel when compared to the other collagen preparations.  
3.5 Summary 
When islets were cultured in the presence of the newly formed humalipogel, islet 
functionality increased. However, when the digestion process was modified in an attempt 
to increase the effect of humalipogel, there was a decrease in humalipogel effectiveness 
that may be attributed to the digestion modification or a poor differentiation of 
preadipocytes. Further, islets cultured in the presence of humalipogel experienced a more 
rapid break down in morphology showing increased cell migration out of the islet. 
However, the cells around the islets may be newly formed insulin-producing β-cells with 
significant implications for islet tissue engineering and transplantation. Further work 
should focus on confirming that the cells appearing around the islet in vitro are β-cells.  
	37	
Chapter 4 
4 Humalipogel for Soft Tissue Reconstruction 
4.1 Introduction 
The American Society of Plastic Surgeons reports that plastic surgeons perform 
five million reconstructive procedures yearly [38]. The number of patients requiring soft 
tissue replacement reconstructive surgery increases every year due to a number of factors. 
Most patients suffer from trauma or tissue loss from accidents or diseases resulting in 
partial resection or in severe cases mastectomy for breast cancer. Soft tissue defects not 
only affect the aesthetic appearance of a patient, but also affect the emotional and mental 
health of a patient [39]. Since current autograft procedures primarily inject isolated fat 
from other sections of the body into the defect, they are unsatisfactory for long-term 
replacement due to poor vascularization and poor adipocyte viability, similar to the 
factors plaguing islet transplantation [39-41]. Tissue engineering strategies offer the 
promise of an ideal adipose tissue substitute capable of predictable soft tissue volume and 
shape as well as a high degree of vascularization [42, 43]. Recent adipose tissue 
engineering strategies have focused on scaffolds seeded with adipocyte precursors [44]; 
of particular interest is the use of naturally derived collagen [45], fibrin [46], and 
hyaluronan [47]. The discovery of adipose tissue as a source of adult multipotent stem 
cells has sparked interest in adipose tissue engineering. The use of scaffolds seeded with 
these adipose-derived adult multipotent stem cells has generated promising results for 
soft tissue reconstruction [48, 49]. However, as with any tissue engineering strategy, the 
scaffold must also be biodegradable and avoid immune response. Since few models have 
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reached the clinical realm, there remains a need to engineer a suitable adipose tissue 
substitute for reconstructive or plastic surgery.  
In this study, the newly formed humalipogel was investigated as a scaffold for 
adipose tissue substitutes in soft tissue defects. The humalipogel makes use of its adipose 
origin and the abundance of extracellular matrix proteins secreted during the 
differentiation process to provide an ideal scaffold for adipose tissue regeneration. To 
investigate the potential of humalipogel as a scaffold for adipose tissue regeneration, the 
in vitro adipogenic potential was compared with that of a normal differentiation 
procedure as well as the necessary control groups.  
4.2 Materials and Methods 
4.2.1 Adipogenic Induction Potential 
To test the adipogenic induction potential of the humalipogel, SGBS cells were 
seeded in 24-well tissue culture plates. The cells were allowed to grow to two days post- 
confluency. At this time, four groups were created. The first group was differentiated 
using the previously described protocol. To account for self-induced differentiation, 
another group was cultured in OF media without supplements. A third group was cultured 
using maintenance media supplemented with 2 μM Rosiglitazone. The final group 
consisted of cells differentiated using maintenance media supplemented with 50 μL of 
humalipogel. The cells were then stained for lipid accumulation using Oil Red O. For Oil 
Red O (Sigma–Aldrich) staining, the adherent cells were fixed in 10% formalin, washed 
and stained with a 0.21% (w/v) Oil Red O solution (60% isopropanol and 40% water). 
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Oil Red O staining was then analyzed using bright field imaging. Images were acquired 
using an EVOS microscope at 20X magnification. 
4.3 Results 
To determine the adipogenic differentiation potential of humalipogel, we used 
humalipogel as a media supplement for confluent SGBS preadipocytes. Bright field 
imaging and Oil Red O staining were used to determine the adipogenesis induction 
potential of the filtered material. The bright field images shown in Figure 15 displayed no 
droplet formation in the untreated preadipocytes. In the normal treated adipocytes, lipid 
droplets could be observed starting on day 4. For the humalipogel overlay, lipid droplets 
began to form on day 4 but did not mature in the same way as the treated adipocytes. The 
untreated preadipocytes served as a control and did not stain for lipid droplets. The 
treated (normal) preadipocytes stained positive for lipid droplets using Oil Red O 
staining, starting on day 4, and continued to develop larger lipid droplets over the course 
of differentiation. Staining of the humalipogel overlay treated preadipocytes confirmed 
the presence of lipid droplets beginning on day 4 and continuing through the 
differentiation. However, the humalipogel treated preadipocytes showed an increased 
number of smaller lipid droplets on day 16 than the normal differentiation preadipocytes, 
as seen in Figure 16. 
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4.4 Discussion 
There is a growing need for a suitable adipose tissue substitute capable of filling a 
defined shape and volume for reconstructive purposes. Here, the use of humalipogel as an 
adipogenesis agonist has been demonstrated. The untreated preadipocytes did not 
accumulate lipid droplets as shown in the bright field images, or stain with Oil Red O for 
lipid droplets, indicating that there is not a self-induced differentiation present in the 
cells. The normal and rosiglitazone treated preadipocytes both developed into mature 
adipocytes as seen by the Oil Red O staining of lipid droplets in the cytoplasm as well as 
their rounded morphology seen in bright field imaging. The humalipogel also induced 
differentiation in preadipocytes, although in a different form. The preadipocytes exposed 
to humalipogel started to show small lipid droplets on Day 4 and the droplets continued 
to increase in number as seen on Day 8.  On Days 12 and 16, some of the lipid droplets in 
the humalipogel-treated adipocytes were similar in size to those in the normal 
differentiation group, but the majority of droplets were similar to the small droplets seen 
on Days 4 and 8. The size of these lipid droplets suggest that adipocytes differentiated 
using humalipogel are more insulin-sensitive than the normal or rosiglitazone 
differentiated adipocytes [50].  Thus, humalipogel could be used for differentiating a 
control group of adipocytes for studying insulin resistance.  
However, a far more significant result is the differentiation potential of 
humalipogel and its potential use as a scaffold for adipose tissue regeneration [51-53]. 
The effectiveness of humalipogel for inducing preadipocyte differentiation to healthy 
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mature adipocytes is the first step in the development of humalipogel as a scaffold for 
soft tissue repair. The inherent advantages of humalipogel as a scaffold, coupled with its 
adipogenic induction potential, is a promising start for soft tissue repair.  
4.5 Summary 
The humalipogel was capable of inducing differentiation in SGBS preadipocytes. 
With the potential to induce differentiation the humalipogel can be used in a variety of 
soft tissue repair situations such as soft tissue defects or breast reconstruction after 
mastectomy. Further,	 the	 humalipogel‐treated	 adipocytes	 yielded	 smaller	 lipid	
droplet	sizes	that	suggest	a	higher	sensitivity	to	insulin	than	adipocytes	treated	with	
rosiglitazone	 or	 the	 normal	 differentiation	 solution.	 Future work on this subject 
should focus on using humalipogel as a scaffold for growing and differentiating 
preadipocytes, as well as determining if humalipogel is effective for differentiating 
human mesenchymal stem cells  
(hMSCs) into mature adipocyte.  
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Chapter 5 
5 Using cells as a Bioreactor for Designer Tissue Engineering 
Scaffolds 
5.1 Introduction 
The previous chapters described the generation of a new biologically active human-
derived scaffold and its use as tissue engineering scaffold. However, as currently 
prepared, the concentrated material generated during differentiation lacks sufficient 
protein concentrations to be useful for some tissue engineering applications. For more 
strenuous applications such as bone tissue engineering, an ideal scaffold would have an 
increased quantity of structural proteins such as collagen as compared with scaffold 
engineering.  To increase the effectiveness of human cells as bioreactors for producing 
tissue engineering scaffolds, techniques for optimizing the production of ECM proteins 
were investigated.  
The effect of mechanical stimuli on cell ECM production is well studied for bone 
tissue engineering applications. A study on osteoblasts cultured in perfusion chambers 
investigated the effect of fluid flow on mineralized matrix deposition [54]. By exposing 
the osteoblasts to varying rates of flow for 16 days, they were able to increase the amount 
of matrix deposited on the scaffold as compared to normal static cultures.  Numerous 
other studies have studied the effect of mechanical stimuli on cultured cell ECM 
production [55-57]. Of the many reactions to mechanical stimuli, the most strategic for 
tissue engineering applications were the alignment and improved production of ECM 
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proteins [58, 59].  During preliminary testing, adipocytes failed to maintain attachment in 
under flow conditions and were washed away. A second proposed method for 
mechanically induced ECM production was to place the cells in a slightly stressed 
environment. This method is founded on the idea that cells will react through signaling 
pathways to stresses to return to homeostasis with their environment. Based on this idea, 
we sought to use trypsin, dispase and collagenase to cleave the cells from their ECM in 
vitro, forcing them to 
generate more ECM to 
return to homeostasis.  
A second method 
for modifying cell ECM 
production is through 
hormonal and nutritional 
stimulation. Recent 
research has discovered 
that bones play a crucial 
part in global energy 
metabolism and adipocyte 
secretion of adipokines [60]. Osteoblast-specific secreted osteocalcin interacts with both 
β -cells and adipocytes, participating in the regulating global energy metabolism. 
Recently published data indicates that osteocalcin effects adiponectin secretion in 
adipocytes [61]. While this demonstrated osteocalcin’s effect on ECM protein secretion 
by mature adipocytes, we investigated a similar effect on differentiating preadipocytes.. 
Figure 17: Metabolic engineering of preadipocytes to 
produce ECM used for islet or soft tissue	
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Extensive research on enhancing collagen and proteoglycan synthesis in skin fibroblasts 
has shown that long term exposure to specific amino acids can increase the production of 
collagen and proteoglycans [62-68]. While these studies focused on the use of topical 
agents to reduce the signs of aging, they suggest that amino acid additives such as 
ascorbic acid [69], proline, glycine and lysine[66] could induce fibroblasts to increase 
extracellular matrix production. Even though these studies were on skin fibroblasts, the 
basic principles reflect the regulation of collagen synthesis and thus should be 
transferable to all cell types that generate collagen, including adipocytes. Similar 
experiments have demonstrated the effect of linoleic acid [70], oleic acid [71], and 
palmitic acid on adipocyte differentiation and lipid accumulation [72, 73]. Adipocytes 
have the unique capacity to store excess free fatty acids as	triglyceride	in	lipid	droplets,	
thus we expect increased lipid accumulation in adipocytes possibly leading to increased 
extracellular matrix remodeling. 
For these reasons we hypothesized that by different nutritional supplements, the 
amount and composition of the secreted basement membrane could be enhanced and 
manipulated for varying applications. 
5.2 Materials and Methods 
5.2.1 Cell Culture 
Cells are expanded as previously described in chapter 2 and seeded in 24-well 
tissue culture plates. Two days after the cells have reached confluency, the differentiation 
media is added. The cells are cultured with the differentiation media for 4 days. On Day 4 
the media is collected, labeled and stored at -20OC. The differentiation media is replaced 
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with maintenance media consisting of DMEM/F12 mix supplemented with 0.008 g 
biotin, 0.004 g pantothenate, 2% penicillin/streptomycin, 0.01 mg/mL human transferrin, 
0.02 units/mL insulin, 100 nM cortisol, 0.2 nM T3 and 2 μM rosiglitazone for the control 
group. For the first condition the maintenance media is supplemented with 2 μM 
rosiglitazone. The Amino Acid 1(AA1) group consisted of maintenance media 
supplemented with 3 mg/mL proline. 5 nM osteocalcin was added to the maintenance 
media for the group labeled Ost. The second Amino acid group, AA2, consisted of 3 
mg/mL hydroxyproline added to the maintenance media. The fatty acid groups consisted 
of oleic acid, palmitic acid, and linoleic acid added to maintenance mediagroups 
individually at a concentration of 50 μM.   The media is then collected on days 6, 8, and 
10. The collected media is labeled and stored at -20OC for further analysis. 
5.2.2 Protein Content Determination 
Protein content was determined using BCA assay (Pierce) with Bovine Serum 
Albumin (BSA) as standard. Briefly, 10 μL samples were added to 200 μL of reagent 
based on bicinchoninic acid, inducing a color change. The absorbance was then measured 
at 562 nm. The protein concentration in the sample was determined based on standard 
curves to yield total protein content of the samples. 
5.2.3 Oil Red Staining 
For Oil Red O (Sigma–Aldrich) staining, adherent cells were fixed in 10% 
formalin, washed and stained with a 0.21% (w/v) Oil Red O solution (60% isopropanol 
and 40% water). Oil Red O staining was then analyzed using bright field imaging. Images 
were acquired using an EVOS microscope at 20X magnification. 
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5.3 Results 
To assess adipocyte differentiation, bright field images were taken of Oil Red 
stained and unstained cells after treatment with adipogenic factors. Bright field images 
taken on day 10 of the treated preadipocytes revealed the formation of large lipid droplets 
in all treated preadipocyte groups. The control group did not show any lipid formation. 
The linoleic acid group showed cell detachment. Oil Red staining confirmed the 
existence of lipid droplets in all test groups, with the largest percentage of differentiation 
occurring in the oleic and palmitic acid groups, and the least in the linoleic acid group. 
The control group showed no staining, indicating that all differentiation was a result of 
treatment and there was no self-induced differentiation. Finally, while the stressed 
condition was a promising idea similar to flow stress, the adipocytes failed to reattach 
after treatment and died.  
 To determine if there was a significant change in protein production in adipocytes 
treated with different media supplements during differentiation, we measured protein 
content on Days 6, 8 and 10.  Days 2 and 4 were not measured because all conditions 
were treated with the same differentiation-inducing media during these days. Protein 
content measurements revealed a negative slope in protein content over the course of 
differentiation, with the highest point generally on day 6 and decreasing over the 
remaining days as seen in Figure 19 with error values expressed as SEM. There is an 
increase in protein production on Day 6 between the linoleic acid supplemented 
differentiation, 1139.8 μg/mL, and the normal differentiation, 1001.35 μg/mL. There was 
also a significant decrease in protein secretion in the oleic acid supplemented media to 
887.71 μg/mL. On Day 8, the proline supplemented media, AA1, showed a marked 
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increase in protein content over the normal differentiation with a value of 858.4 μg/mL as 
opposed to 784.8 μg/mL for the normal differentiation. Also, linoleic acid continued to 
show an increase in protein secretion on Day 8 with a value of 884.1 μg/mL. Further 
evaluation of protein secretion in terms of percent change compared to normal shows that 
only linoleic acid significantly increased production content in the media over the test 
period, Figure 20. Figures 21 and 22 show a detailed comparison amongst the groups on 
Day 6 and 8 respectively with statistical analysis.  
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5.4 Discussion 
One of the main challenges of tissue replacement therapies is the ability to 
generate biological material within cell seeded supports after transplantation [74]. To 
decrease the amount of initial time and material needed for cell seeded scaffolds to 
successfully attach to the damaged area, it is desirable for the cells to produce their own 
ECM as well as use the starting material provided by the scaffold. Based on published 
evidence indicating that certain nutritional supplements can increase the ECM production 
in skin cells when applied topically, we hypothesized that the same nutritional and 
hormonal supplements could increase ECM production in human preadipocytes in vitro 
during differentiation, effectively using the preadipocytes as a bioreactor to produce 
ECM based on the effects of different media supplements.  
The protein content results that linoleic acid, palmitic acid and proline are all 
capable of increasing the yield of ECM within the collected media, although palmitic 
acid- increased secretion was not statistically significant. Linoleic acid was the only 
supplement to increase protein secretion over the whole differentiation process and has 
not been previously reported. Prior studies have shown that linoleic acid promotes lipid 
filling of murine adipocytes while inhibiting proliferation [70]. The increased lipid 
accumulation is also seen in this study in Figure 18. A possible explanation for increased 
protein secretion is that the increased lipid accumulation required an increase in 
extracellular matrix remodeling and ultimately produced more proteins for the process.  
Oleic acid also demonstrated an increase protein secretion on Day 8 and increased lipid 
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accumulation. While the increased protein secretion was only 5%	 higher	 than	 the	
normal‐differentiated	 group,, the increased lipid accumulation was expected from 
previous studies [71].  Palmitic acid-treated adipocytes also demonstrated a high degree 
of lipid accumulation, an expected result when compared with previous studies on 
adipocytes [75, 76].   The	unique	capacity	of	adipocytes	for	storing	excess	free	fatty	
acids	 in	 lipid	 droplets	 as	 triglyceride	 was	 demonstrated	 in	 the	 fatty	 acid‐treated	
conditions,	along	with	increased	protein	secretion	seen	in	the	palmitic	and	lanoleic	
cases.				
The increased protein content in the proline condition was consistent with the 
published results in skin fibroblasts, demonstrating that proline supplementation does 
increase ECM production [63, 77]. The protein content in the proline-treated adipocytes 
was 10% greater on Day 8. Hydroxyproline was not expected to produce an increase in 
protein secretion, because only the hydroxylation of proline and lysine by proline 
hydroxylase and lysine hydroxylase allows collagen synthesis to proceed in vivo [66].  
Rosiglitazone and osteocalcin both produced a decrease in protein secretion. However, 
these conditions detached from the culture plates during the second experiment. During 
the first trial, they produced levels of protein during differentiation similar to the normal 
differentiation. While the secreted protein was not quantitatively characterized, the ability 
to increase or decrease protein secretion by preadipocytes during differentiation 
demonstrates the usefulness of cells as a bioreactor for engineering designer tissue 
engineering scaffolds based on application constraints. 
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5.5 Summary 
The findings of this study demonstrate the ability to modulate the amount of protein 
secreted from the adipocytes during differentiation based on nutritional and hormonal 
supplements. From this testing, the most effective stimulants for increasing protein 
production were proline, oleic acid, and linoleic acid. Further through this method, we 
have shown that adipocytes, and possibly other cells with ECM protein synthesis 
pathways, may be used as bioreactors for engineering designer tissue-scaffolds based on 
specific application constraints. Future work in this topic should focus on characterizing 
the proteins secreted during treatment and the use of different cell types to generate a 
specific ECM microenvironment.  
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Chapter 6 
6 Summary and Future Directions 
 
To attempt to overcome the shortcomings, including immune response and lack of 
donors, of current tissue engineering scaffolds, our goal was to use human adipocytes to 
generate a material capable of serving as a tissue engineering material free of pathogens.  
The technique developed uses the differentiation of preadipocytes as the primary source 
of extracellular matrix proteins. During the differentiation from preadipocytes to 
adipocytes, the morphology of the cells changes. As the cells differentiate, to compensate 
for the changing morphology, they produce ECM proteins to remodel their extracellular 
matrix surroundings [78]. The technique collects the secreted ECM proteins and filters 
them for use as a tissue engineering scaffold. To enhance the production of ECM proteins 
during differentiation, different supplements are used to stimulate ECM production. This 
work lays the framework for developing a method for producing a human adipocyte-
derived extracellular matrix material with defined composition and capable of being 
manipulated for varying tissue engineering applications. Future work with this material 
should focus on quantifying the secretome of adipocytes during differentiation. 
One of the most daunting challenges faced in tissue engineering is finding a safe, 
abundant source of scaffolding material. While polymer-based scaffolds are naturally 
derived, studies have shown they still incite foreign body responses [79-83]. Animal 
tissues have served as an alternative to synthetic scaffolds, yet they lack the same 
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biological composition as the human extracellular matrix [84]. The developed material 
offers several advantages over current scaffold systems. Due to the culture conditions, the 
material should be pathogen-free and is derived from human preadipocytes thus, as 
shown in another study [85], should not elicit a host immune response. Also, due to the 
human cell origin, the material closely resembles endogenous human tissue. Finally, this 
technique can completely eliminate any host response by using patient-derived cells to 
generate the scaffolding. Although the production of material from the patient-derived 
adipocytes would require an additional harvesting operation with an extended culture 
period, the resulting material could be coupled with patient-derived stem cells to create 
an individually-matched cell therapy for damaged tissue. 
6.1 Future Directions 
While this approach suggests a patient-matched method for overcoming immune 
response, the additional operation and extended culture period are drawbacks of this 
method. Future work in this area should revolve around developing an autologous 
extracellular matrix scaffold capable of use in all patients and free of the extended culture 
period. Research into the creation of an autologous matrix has already begun. 
Researchers at the University of Tsukuba developed a material by decellularizing a 
template seeded with autologous cells [86]. After removing the template, the remaining 
ECM demonstrated a high degree of biocompatibility. While this method still exposes the 
matrix to exogenous materials and requires further development, they demonstrated the 
potential development of an autologous extracellular matrix. Future directions should 
also include mapping the precise relationship between stimulants and the secreted ECM. 
While the precise conditions for producing a specific product will vary by cell type, the 
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ability to enhance cell-secreted matrix should be further developed. Manipulating the 
cell’s secretome would naturally progress towards using cells as bioreactors to meet 
design criteria for assorted applications. Another part of the cell as a bioreactor concept is 
the use of different cell types in co-culture to produce a biomaterial that more closely 
mimics the native environment of the desired tissue.  
Cell-secreted extracellular matrix is a promising new material for tissue 
engineering applications, offering a naturally-derived material capable of mimicking the 
complexity of native ECM while avoiding eliciting foreign body inflammatory response 
from the host. Although most recent studies demonstrate the use of cell-secreted ECM 
from various cell sources as producing favorable results for enhancing cell proliferation 
and function on decellularized polymer scaffolds, there remains the ability to use the 
ECM as reconstituted scaffold similar to matrigel, capable of taking different geometries 
based on application constraints. Future work with cell-secreted ECM also elicits ideas of 
metabolically engineering mammalian cells for production of large quantities of ECM 
containing high concentrations of vital growth factors. While the use of multiple cell 
types in co-culture and metabolically manipulating cells to produce a biomaterial that 
resembles the native structure of the desired tissue has yet to be established, cell-secreted 
ECM holds the promise of producing an ideal biomaterial for tissue engineering.  
6.2 Potential Clinical Applications: 
 As we have previously discussed in chapter 3, one of the most promising 
applications for humalipogel is as a scaffold for encapsulating islets for transplantation. 
Research has shown that islets cultured in 3-dimensional structures have improved 
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function and viability for transplantation. The developed basement membrane would 
duplicate the peri-insular basement membrane and cell-cell interactions in the islets 
increasing islet survival. Another challenge in islet engineering and transplantation is the 
lack of vascularization. A basement membrane in mice has been shown to promote 
angiogenesis and endothelial cells co-cultured with adipocytes have been shown to have 
increased tube formation [17]. These results suggest that humalipogel would promote 
vascularization and survival in isolated and transplanted islets as well as possibly 
promoting β-cell proliferation. An even more intriguing aspect of humalipogel is the 
potential to stimulate B-cell proliferation in vitro. If humalipogel is promoting B-cell 
proliferation, B-cells could be expanded in vitro to decrease the number of donors needed 
per islet transplant, then encapsulated in humalipogel and transplanted to the patient. 
Another challenge to islet transplant and engineering is protecting the islets from the 
host’s immune response. With a naturally derived membrane, the islets would be 
protected from the immune response of the host. 
 Humalipogel provides a safe method for delivering cells to target sites as well as 
providing the extracellular matrix to assist in cell proliferation and differentiation. The 
ability to induce secretion of growth factors, hormones and cytokines into the membrane 
through different stimulants allows us to design a membrane for the specific application. 
In this way, humalipogel could be used for treating spinal cord injuries. By encapsulating 
human mesenchymal stem cells (hMSCs) in the derived membrane, the cells could be 
safely delivered to the injury site. The hMSCs would be delivered to the site with the 
necessary growth factors as well as extracellular matrix for cell differentiation and 
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proliferation, eventually the humalipogel would be degraded by the expanding cells and 
replaced with the naturally occurring ECM of the expanding cell population.  
A similar application as spinal cord injuries, humalipogel could be used for bone 
tissue engineering applications. The humalipogel can be designed to promote bone tissue 
remodeling by increasing the amount of osteoprotegrin and osteopontin as well as 
increasing the collagen content in the gel for structural integrity. Humalipogel can then be 
used as a basement membrane for bone reconstruction. The humalipogel could be 
coupled with a polymer scaffold to promote bone growth in injured areas such as the face 
or legs or with increased collagen content as its own scaffold. The polymer scaffold 
would provide the structural integrity to fill the void of the injury while humalipogel was 
used to recruit and promote bone formation around the scaffolding. 
 Another potential clinical application for the use of humalipogel is wound 
healing. Wound healing is dependent on angiogenesis. As previously discussed, 
humalipogel is expected to promote angiogensis based on the mouse model [17] and 
previous research [25]. The advantage of our system is that we are capable of producing a 
membrane from a human system allowing for the direct application of humalipogel to the 
wound. All of the potential clinical applications are predicated on the unique flexibility of 
the adipocytes to be used a bioreactor and manipulated to produce a designer 
extracellular matrix scaffold. 
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